Sintilimab combined with chemotherapy successfully treated a patient with advanced submandibular gland tumor.

Abstract

Primary submandibular gland tumors arerelatively rare. Due to its low incidence and broad spectrum phenotypic, biologicaland clinical heterogeneity types, a wide range of options have been developed to treat this tumor. To date, however, efficacious standard treatment regimens are lacking. Here, the authors present a case ofa patient withan advanced submandibular gland tumor. Histological and imaging results diagnosed the case as stage IV submandibular gland adenocarcinoma with multiple metastases. The patient was subjected to systemic platinum-based chemotherapy combined with sintilimab. Aprimary lesion complete responsewas observed after six cycles of treatment. This case affirms theefficacy of thePD-1inhibitor sintilimab combined with platinum-based chemotherapy as a first-line treatment for advanced submandibular gland tumors.